메뉴 건너뛰기




Volumn 90, Issue 12, 2015, Pages 1639-1649

Characteristics of Exceptional or Super Responders to Cancer Drugs

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

EID: 84953236641     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.08.017     Document Type: Article
Times cited : (34)

References (51)
  • 1
    • 84923808557 scopus 로고    scopus 로고
    • Biomarkers: Exceptional responders-discovering predictive biomarkers
    • N. Takebe, L. McShane, and B. Conley Biomarkers: exceptional responders-discovering predictive biomarkers Nat Rev Clin Oncol 12 3 2015 132 134
    • (2015) Nat Rev Clin Oncol , vol.12 , Issue.3 , pp. 132-134
    • Takebe, N.1    McShane, L.2    Conley, B.3
  • 2
    • 84901829381 scopus 로고    scopus 로고
    • Learning from exceptional drug responders
    • A. Mullard Learning from exceptional drug responders Nat Rev Drug Discov 13 6 2014 401 402
    • (2014) Nat Rev Drug Discov , vol.13 , Issue.6 , pp. 401-402
    • Mullard, A.1
  • 3
    • 84973667267 scopus 로고    scopus 로고
    • NCI starts 'exceptional responder' hunt
    • A. Mullard NCI starts 'exceptional responder' hunt Nat Rev Drug Discov 13 11 2014 803
    • (2014) Nat Rev Drug Discov , vol.13 , Issue.11 , pp. 803
    • Mullard, A.1
  • 4
    • 84941118318 scopus 로고    scopus 로고
    • In search of exceptional responders
    • In search of exceptional responders Cancer Discov 5 1 2015 8
    • (2015) Cancer Discov , vol.5 , Issue.1 , pp. 8
  • 5
    • 84921024765 scopus 로고    scopus 로고
    • Cancer centers zero in on exceptional responders
    • Erratum in Nat Biotechnol. 2014;32(11):1074. Dosage error in article text
    • C. Sheridan Cancer centers zero in on exceptional responders Nat Biotechnol 32 8 2014 703 704 Erratum in Nat Biotechnol. 2014;32(11):1074. Dosage error in article text
    • (2014) Nat Biotechnol , vol.32 , Issue.8 , pp. 703-704
    • Sheridan, C.1
  • 6
    • 84928403539 scopus 로고    scopus 로고
    • Cancer: A most exceptional response
    • V. Marx Cancer: a most exceptional response Nature 520 7547 2015 389 393
    • (2015) Nature , vol.520 , Issue.7547 , pp. 389-393
    • Marx, V.1
  • 7
    • 84887462642 scopus 로고    scopus 로고
    • "n of 1" case reports in the era of whole-genome sequencing
    • A.R. Brannon, and C.L. Sawyers "N of 1" case reports in the era of whole-genome sequencing J Clin Invest 123 11 2013 4568 4570
    • (2013) J Clin Invest , vol.123 , Issue.11 , pp. 4568-4570
    • Brannon, A.R.1    Sawyers, C.L.2
  • 10
    • 84907863603 scopus 로고    scopus 로고
    • Response and acquired resistance to everolimus in anaplastic thyroid cancer
    • N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer N Engl J Med 371 15 2014 1426 1433
    • (2014) N Engl J Med , vol.371 , Issue.15 , pp. 1426-1433
    • Wagle, N.1    Grabiner, B.C.2    Van Allen, E.M.3
  • 12
    • 79959627009 scopus 로고    scopus 로고
    • Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies [in French]
    • A.S. Thonnard, L. Bosquee, and J.L. Corhay Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies [in French] Rev Med Liege 66 3 2011 121 125
    • (2011) Rev Med Liege , vol.66 , Issue.3 , pp. 121-125
    • Thonnard, A.S.1    Bosquee, L.2    Corhay, J.L.3
  • 13
    • 84940501179 scopus 로고    scopus 로고
    • Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma
    • Y. Godbert, B. Henriques de Figueiredo, F. Bonichon, and et al. Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma J Clin Oncol 33 20 2015 e84 e87
    • (2015) J Clin Oncol , vol.33 , Issue.20 , pp. e84-e87
    • Godbert, Y.1    Henriques De Figueiredo, B.2    Bonichon, F.3
  • 14
    • 84978022583 scopus 로고    scopus 로고
    • Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
    • A. Takalkar, S. Adams, and V. Subbiah Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone Exp Hematol Oncol 3 2014 23
    • (2014) Exp Hematol Oncol , vol.3 , pp. 23
    • Takalkar, A.1    Adams, S.2    Subbiah, V.3
  • 15
    • 84909589393 scopus 로고    scopus 로고
    • Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: Implementation of a molecular tumour board and next-generation sequencing for personalized medicine
    • A. Loaiza-Bonilla, E. Clayton, E. Furth, M. O'Hara, and J. Morrissette Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine Ecancermedicalscience 8 2014 479
    • (2014) Ecancermedicalscience , vol.8 , pp. 479
    • Loaiza-Bonilla, A.1    Clayton, E.2    Furth, E.3    O'Hara, M.4    Morrissette, J.5
  • 16
    • 84869206991 scopus 로고    scopus 로고
    • Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
    • V. Subbiah, R.E. Brown, J. Buryanek, and et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Mol Cancer Ther 11 11 2012 2541 2546
    • (2012) Mol Cancer Ther , vol.11 , Issue.11 , pp. 2541-2546
    • Subbiah, V.1    Brown, R.E.2    Buryanek, J.3
  • 17
    • 84904304127 scopus 로고    scopus 로고
    • Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy
    • M. Ilander, P. Koskenvesa, S. Hernesniemi, T. Lion, K. Porkka, and S. Mustjoki Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy Leuk Lymphoma 55 4 2014 934 937
    • (2014) Leuk Lymphoma , vol.55 , Issue.4 , pp. 934-937
    • Ilander, M.1    Koskenvesa, P.2    Hernesniemi, S.3    Lion, T.4    Porkka, K.5    Mustjoki, S.6
  • 18
    • 79953742425 scopus 로고    scopus 로고
    • Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures
    • V. Subbiah, A. Naing, R.E. Brown, and et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures PLoS One 6 4 2011 e18424
    • (2011) PLoS One , vol.6 , Issue.4 , pp. e18424
    • Subbiah, V.1    Naing, A.2    Brown, R.E.3
  • 19
    • 84908288657 scopus 로고    scopus 로고
    • Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
    • V. Subbiah, F. Meric-Bernstam, G.B. Mills, and et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial J Hematol Oncol 7 2014 52
    • (2014) J Hematol Oncol , vol.7 , pp. 52
    • Subbiah, V.1    Meric-Bernstam, F.2    Mills, G.B.3
  • 20
    • 84994493627 scopus 로고    scopus 로고
    • Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma
    • E.M. Van Allen, V.W. Lui, A.M. Egloff, and et al. Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma JAMA Oncol 1 2 2015 238 244
    • (2015) JAMA Oncol , vol.1 , Issue.2 , pp. 238-244
    • Van Allen, E.M.1    Lui, V.W.2    Egloff, A.M.3
  • 21
    • 84893823864 scopus 로고    scopus 로고
    • A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
    • V. Subbiah, R.E. Brown, M.F. McGuire, and et al. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma Oncotarget 5 1 2014 95 102
    • (2014) Oncotarget , vol.5 , Issue.1 , pp. 95-102
    • Subbiah, V.1    Brown, R.E.2    McGuire, M.F.3
  • 22
    • 84922254940 scopus 로고    scopus 로고
    • Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma
    • D.L. Bajor, X. Xu, D.A. Torigian, and et al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma Cancer Immunol Res 2 11 2014 1051 1058
    • (2014) Cancer Immunol Res , vol.2 , Issue.11 , pp. 1051-1058
    • Bajor, D.L.1    Xu, X.2    Torigian, D.A.3
  • 23
    • 38449097977 scopus 로고    scopus 로고
    • Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly
    • A. Berrebi, E. Feldberg, I. Spivak, and L. Shvidel Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly Haematologica 92 2 2007 e15 e16
    • (2007) Haematologica , vol.92 , Issue.2 , pp. e15-e16
    • Berrebi, A.1    Feldberg, E.2    Spivak, I.3    Shvidel, L.4
  • 24
    • 84908363886 scopus 로고    scopus 로고
    • Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
    • C.M. Lovly, N.T. McDonald, H. Chen, and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat Med 20 9 2014 1027 1034
    • (2014) Nat Med , vol.20 , Issue.9 , pp. 1027-1034
    • Lovly, C.M.1    McDonald, N.T.2    Chen, H.3
  • 25
    • 84874459104 scopus 로고    scopus 로고
    • Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer
    • K. Hashimoto, H. Horinouchi, T. Ohtsuka, and et al. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer Gen Thorac Cardiovasc Surg 60 12 2012 851 854
    • (2012) Gen Thorac Cardiovasc Surg , vol.60 , Issue.12 , pp. 851-854
    • Hashimoto, K.1    Horinouchi, H.2    Ohtsuka, T.3
  • 26
    • 84857090723 scopus 로고    scopus 로고
    • Phase i study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
    • A.I. Daud, S.S. Krishnamurthi, M.N. Saleh, and et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors Clin Cancer Res 18 4 2012 1092 1100
    • (2012) Clin Cancer Res , vol.18 , Issue.4 , pp. 1092-1100
    • Daud, A.I.1    Krishnamurthi, S.S.2    Saleh, M.N.3
  • 27
    • 84860524932 scopus 로고    scopus 로고
    • A phase i pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class i selective histone deacetylase inhibitor in refractory solid tumors
    • U. Banerji, L. van Doorn, D. Papadatos-Pastos, and et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors Clin Cancer Res 18 9 2012 2687 2694
    • (2012) Clin Cancer Res , vol.18 , Issue.9 , pp. 2687-2694
    • Banerji, U.1    Van Doorn, L.2    Papadatos-Pastos, D.3
  • 28
    • 77649215630 scopus 로고    scopus 로고
    • Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors
    • A.J. Wagner, I. Malinowska-Kolodziej, J.A. Morgan, and et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 5 2010 835 840
    • (2010) J Clin Oncol , vol.28 , Issue.5 , pp. 835-840
    • Wagner, A.J.1    Malinowska-Kolodziej, I.2    Morgan, J.A.3
  • 29
    • 84866301785 scopus 로고    scopus 로고
    • Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer
    • M. Zhang, A. Mahta, R.Y. Kim, S. Akar, and S. Kesari Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer Med Oncol 29 2 2012 806 808
    • (2012) Med Oncol , vol.29 , Issue.2 , pp. 806-808
    • Zhang, M.1    Mahta, A.2    Kim, R.Y.3    Akar, S.4    Kesari, S.5
  • 30
    • 84898732516 scopus 로고    scopus 로고
    • Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
    • M.H. Voss, A.A. Hakimi, C.G. Pham, and et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Clin Cancer Res 20 7 2014 1955 1964
    • (2014) Clin Cancer Res , vol.20 , Issue.7 , pp. 1955-1964
    • Voss, M.H.1    Hakimi, A.A.2    Pham, C.G.3
  • 31
    • 84906903083 scopus 로고    scopus 로고
    • Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy
    • H. Al-Ahmadie, G. Iyer, M. Hohl, and et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy Cancer Discov 4 9 2014 1014 1021
    • (2014) Cancer Discov , vol.4 , Issue.9 , pp. 1014-1021
    • Al-Ahmadie, H.1    Iyer, G.2    Hohl, M.3
  • 32
    • 84892379425 scopus 로고    scopus 로고
    • Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
    • V. Subbiah, S.N. Westin, K. Wang, and et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein J Hematol Oncol 7 2014 8
    • (2014) J Hematol Oncol , vol.7 , pp. 8
    • Subbiah, V.1    Westin, S.N.2    Wang, K.3
  • 33
    • 84942989099 scopus 로고    scopus 로고
    • Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification
    • N. Palma, J.C. Morris, S.M. Ali, J.S. Ross, and S.K. Pal Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification Eur Urol 68 1 2015 168 170
    • (2015) Eur Urol , vol.68 , Issue.1 , pp. 168-170
    • Palma, N.1    Morris, J.C.2    Ali, S.M.3    Ross, J.S.4    Pal, S.K.5
  • 34
    • 84929999263 scopus 로고    scopus 로고
    • Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation
    • S.M. Ali, V.A. Miller, J.S. Ross, and S.K. Pal Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation Eur Urol 67 6 2015 1195 1196
    • (2015) Eur Urol , vol.67 , Issue.6 , pp. 1195-1196
    • Ali, S.M.1    Miller, V.A.2    Ross, J.S.3    Pal, S.K.4
  • 35
    • 84899680978 scopus 로고    scopus 로고
    • Activating mTOR mutations in a patient with an extraordinary response on a phase i trial of everolimus and pazopanib
    • N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov 4 5 2014 546 553
    • (2014) Cancer Discov , vol.4 , Issue.5 , pp. 546-553
    • Wagle, N.1    Grabiner, B.C.2    Van Allen, E.M.3
  • 36
    • 84867333656 scopus 로고    scopus 로고
    • Genome sequencing identifies a basis for everolimus sensitivity
    • G. Iyer, A.J. Hanrahan, M.I. Milowsky, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 6104 2012 221
    • (2012) Science , vol.338 , Issue.6104 , pp. 221
    • Iyer, G.1    Hanrahan, A.J.2    Milowsky, M.I.3
  • 37
    • 84982893727 scopus 로고    scopus 로고
    • Five years of cancer drug approvals: Innovation, efficacy, and costs
    • S. Mailankody, and V. Prasad Five years of cancer drug approvals: innovation, efficacy, and costs JAMA Oncol 1 4 2015 539 540
    • (2015) JAMA Oncol , vol.1 , Issue.4 , pp. 539-540
    • Mailankody, S.1    Prasad, V.2
  • 38
    • 55249092961 scopus 로고    scopus 로고
    • Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: Analysis of the surveillance, epidemiology, and end results 1983-2002
    • J. Chen, J.D. Tward, D.C. Shrieve, and Y.J. Hitchcock Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002 Am J Clin Oncol 31 5 2008 460 464
    • (2008) Am J Clin Oncol , vol.31 , Issue.5 , pp. 460-464
    • Chen, J.1    Tward, J.D.2    Shrieve, D.C.3    Hitchcock, Y.J.4
  • 39
    • 79958043675 scopus 로고    scopus 로고
    • National Cancer Institute seer.cancer.gov Web site. Accessed September 10, 2015
    • National Cancer Institute. SEER cancer statistics review 1975-2012. seer.cancer.gov Web site. http://seer.cancer.gov/csr/1975-2012/results-merged/sect-22-pancreas.pdf. Accessed September 10, 2015.
    • SEER Cancer Statistics Review 1975-2012
  • 40
    • 84961708815 scopus 로고    scopus 로고
    • aboutcancer.com Web site. Accessed September 10, 2015
    • Survival statistics for cancer of the pancreas. aboutcancer.com Web site. http://www.aboutcancer.com/pancreas3.htm. Accessed September 10, 2015.
    • Survival Statistics for Cancer of the Pancreas
  • 41
    • 84892701195 scopus 로고    scopus 로고
    • The accelerated approval of oncologic drugs: Lessons from ponatinib
    • V. Prasad, and S. Mailankody The accelerated approval of oncologic drugs: lessons from ponatinib JAMA 311 4 2014 353 354
    • (2014) JAMA , vol.311 , Issue.4 , pp. 353-354
    • Prasad, V.1    Mailankody, S.2
  • 42
    • 0020590588 scopus 로고
    • Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
    • M. Talpaz, K.B. McCredie, G.M. Mavligit, and J.U. Gutterman Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia Blood 62 3 1983 689 692
    • (1983) Blood , vol.62 , Issue.3 , pp. 689-692
    • Talpaz, M.1    McCredie, K.B.2    Mavligit, G.M.3    Gutterman, J.U.4
  • 43
    • 84876100195 scopus 로고    scopus 로고
    • Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
    • M. Talpaz, R. Hehlmann, A. Quintás-Cardama, J. Mercer, and J. Cortes Re-emergence of interferon-α in the treatment of chronic myeloid leukemia Leukemia 27 4 2013 803 812
    • (2013) Leukemia , vol.27 , Issue.4 , pp. 803-812
    • Talpaz, M.1    Hehlmann, R.2    Quintás-Cardama, A.3    Mercer, J.4    Cortes, J.5
  • 44
    • 84928582479 scopus 로고    scopus 로고
    • Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
    • D.V. Catenacci Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity Mol Oncol 9 5 2015 967 996
    • (2015) Mol Oncol , vol.9 , Issue.5 , pp. 967-996
    • Catenacci, D.V.1
  • 45
    • 84928503242 scopus 로고    scopus 로고
    • What have we learned from exceptional tumour responses? Review and perspectives
    • N. Mehra, D. Lorente, and J.S. de Bono What have we learned from exceptional tumour responses? Review and perspectives Curr Opin Oncol 27 3 2015 267 275
    • (2015) Curr Opin Oncol , vol.27 , Issue.3 , pp. 267-275
    • Mehra, N.1    Lorente, D.2    De Bono, J.S.3
  • 46
    • 84927154472 scopus 로고    scopus 로고
    • Basket trials and the evolution of clinical trial design in an era of genomic medicine
    • A.J. Redig, and P.A. Jänne Basket trials and the evolution of clinical trial design in an era of genomic medicine J Clin Oncol 33 9 2015 975 977
    • (2015) J Clin Oncol , vol.33 , Issue.9 , pp. 975-977
    • Redig, A.J.1    Jänne, P.A.2
  • 47
    • 84880991913 scopus 로고    scopus 로고
    • 'Basket studies' will hold intricate data for cancer drug approvals
    • C. Willyard 'Basket studies' will hold intricate data for cancer drug approvals Nat Med 19 6 2013 655
    • (2013) Nat Med , vol.19 , Issue.6 , pp. 655
    • Willyard, C.1
  • 48
    • 78649932986 scopus 로고    scopus 로고
    • The mean does not mean as much anymore: Finding subgroups for tailored therapeutics
    • S.J. Ruberg, L. Chen, and Y. Wang The mean does not mean as much anymore: finding subgroups for tailored therapeutics Clin Trials 7 5 2010 574 583
    • (2010) Clin Trials , vol.7 , Issue.5 , pp. 574-583
    • Ruberg, S.J.1    Chen, L.2    Wang, Y.3
  • 49
    • 84939825159 scopus 로고    scopus 로고
    • The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses
    • V. Prasad, C. Kim, M. Burotto, and A. Vandross The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses JAMA Intern Med 175 8 2015 1389 1398
    • (2015) JAMA Intern Med , vol.175 , Issue.8 , pp. 1389-1398
    • Prasad, V.1    Kim, C.2    Burotto, M.3    Vandross, A.4
  • 50
    • 84927606243 scopus 로고    scopus 로고
    • Lung Master Protocol (Lung-MAP) - A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400
    • R.S. Herbst, D.R. Gandara, F.R. Hirsch, and et al. Lung Master Protocol (Lung-MAP) - a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400 Clin Cancer Res 21 7 2015 1514 1524
    • (2015) Clin Cancer Res , vol.21 , Issue.7 , pp. 1514-1524
    • Herbst, R.S.1    Gandara, D.R.2    Hirsch, F.R.3
  • 51


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.